Nikolay Savchuk
Managing General Partner @ Teal Ventures Fund I
San Diego, United States
Nikolay Savchuk is a seed investor at Teal Ventures Fund I in San Diego focused on Biotechnology and Medical. Nikolay Savchuk Ph.D. is a serial entrepreneur and experienced international investor in the healthcare and IT industries for 23 years. Dr. Savchuk is the co-founder and Managing Partner at San Diego-based Torrey Pines Investment LLC, Chairman of the Board of ChemDiv Inc and Viriom Inc.The scope of main interest of Dr. Savchuk is life sciencesincluding rational drug design, AI and expert systems design control science, drug discovery and digital health technologies. Dr. Savchuk led and continues to manage successful investments in pharmaceutical and drug development companies. Dr. Savchuk obtained the MS degree in physics in 1994 and Ph.D. in applied mathematics in 2000 from Moscow Institute of Physics and Technology. He is an inventor and author of over 100 patents and research publications.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Nikolay Savchuk invests in
Stages Nikolay Savchuk invests in
Countries Nikolay Savchuk invests in
Investment Focus
Industry
- Biotechnology 3 (75%)
- Medical 1 (25%)
- Real Time 1 (25%)
- Health Care 1 (25%)
- Life Science 1 (25%)
Stage
- Seed 1 (25%)
- Series A 1 (25%)
- Series B 1 (25%)
Country
- United States 2 (50%)
- Portugal 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Mondego Bio
|
Headquartered in Portugal’s main biotech park, Biocant, Mondego Bio is developing best-in-class protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitors, providing a potential immuno-oncological therapy with an improved safety and tolerability profile. | Series A / Sep 18, 2025 | |
Avelas Biosciences
|
At Avelas Biosciences, their mission is to advance a new standard-of-care in cancer surgery by providing a real time luminous map for oncologic surgeons, leading to improved surgical results and better outcome for patients. | $7.4M / Series B / Sep 10, 2014 | |
|
Avelas Biosciences
|
At Avelas Biosciences, their mission is to advance a new standard-of-care in cancer surgery by providing a real time luminous map for oncologic surgeons, leading to improved surgical results and better outcome for patients. | $6.8M / Series B / Jan 09, 2014 | |
Chromis Therapeutics
|
Chromis Therapeutics, Inc. (Chromis) is a San Diego-based biopharmaceutical company, focused on the development of curative treatments for chronic HBV infection, based on its advanced proprietary drug design and discovery platform. The company is seeking investment to advance its novel cccDNA inhibitor (CHR101), viral entry and viral capsidassembly inhibitor lead candidates for the treatment of chronic HBV. CHR101 has a potential to eradicate HBV and to efficiently cure chronically infected HBV patients, as compared to drugs currently on the market. CHR101's activity is supported by a robust discovery preclinical data package. | $3M / Seed |
Co-Investors
About Teal Ventures Fund I
Teal Ventures Fund I Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Nikolay Savchuk
Managing General Partner
|
|||
4 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Nikolay Savchuk invest in?
Nikolay Savchuk invests primarily in Biotechnology, Medical and Real Time startups, most often at Seed and Series A stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Nikolay Savchuk last invest?
The most recent investment recorded for Nikolay Savchuk closed in Sep 2025. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
